Bispecific antibodies are able to bind simultaneously to two separate unique antigens, or even epitopes of the same antigen. One of the most widely used applications for this tool is in the study and development of cancer immunotherapies.
InvivoGen offers bispecific antibodies consisting of single chain variable fragments (scFvs) from two different monoclonal antibodies joined by a glycine-serine linker and tagged with a hexahistidine (His6-tag). They can be used to study B cell contact-dependent killing or T cell activation.
Negative controls for the bispecific antibodies with E. coli β-galactosidase specificity for both binding sites are also available. InvivoGen also offers other clinically relevant biosimilar antibodies and their corresponding isotype controls.